CDEK
← All drugs Report issue

as01

Small moleculeexperimental

Clinical trial activity

28 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
20
Phase 2
18
Phase 3
3
Phase 4
0

Earliest trial started Dec 1, 2003 (NCT00075049)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • UnclearImmunity, active

    Unclear immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • as01
  • as01b
  • as01e
  • as01e1
  • aso1b

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06062238Phase 3Feb 29, 2024Bill and Melinda Gates Foundation, Wellcome Trust
NCT04556981Phase 2Nov 17, 2020Bill and Melinda Gates Foundation
NCT04319380Phase 3May 31, 2020Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO), Institut et Haute école de la Santé, La Source, Malaria Research and Training Center, Bamako, Mali, University of London
NCT04090658Phase 1Sep 23, 2019GlaxoSmithKline
NCT04026009Phase 1Aug 5, 2019GlaxoSmithKline
NCT03894969Phase 2Apr 29, 2019GlaxoSmithKline
NCT03866187Phase 1Mar 28, 2019GlaxoSmithKline
NCT03814590Phase 1Jan 21, 2019GlaxoSmithKline
NCT03547245Phase 1Jun 15, 2018George Washington University, International AIDS Vaccine Initiative, University of Washington
NCT03122223Phase 1/Phase 2 (Phase 2)Jun 5, 2017GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), Sanofi-Aventis, University of California, San Francisco
NCT02992119Phase 2Jun 4, 2017Mahidol University, University of Oxford
NCT03162614Phase 2May 23, 2017GlaxoSmithKline, PATH
NCT03143218Phase 3Apr 17, 2017Institut et Haute école de la Santé, La Source, Malaria Research and Training Center, Bamako, Mali, University of London
NCT02915016Phase 1/Phase 2 (Phase 2)Dec 1, 2016Centre for the AIDS Programme of Research in South Africa, National Institute of Allergy and Infectious Diseases (NIAID)
NCT02942277Phase 1Oct 6, 2016National Institute of Allergy and Infectious Diseases (NIAID)
NCT02600975Phase 1Dec 8, 2015University of Oxford
NCT02252640Phase 1/Phase 2 (Phase 2)Jan 1, 2015National Institute for Health Research, United Kingdom, PATH, University of Oxford
NCT02174978Phase 1Aug 1, 2014GlaxoSmithKline, United States Agency for International Development, United States Army
NCT02044198Phase 1/Phase 2 (Phase 2)Mar 1, 2014Moorgreen Hospital, Southampton, National Institute for Health Research, United Kingdom, PATH, University of London, University of Oxford
NCT01883609Phase 1/Phase 2 (Phase 2)Sep 1, 2013Moorgreen Hospital, Southampton, University of London, University of Oxford
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit15622003
United States ArmyGovernment8822003
PATHAcademic/Hospital6012006
University of OxfordAcademic/Hospital5522013
University of LondonAcademic/Hospital4222013
National Institute of Allergy and Infectious Diseases (NIAID)Government3322016
Bill and Melinda Gates FoundationAcademic/Hospital2222020
Institut et Haute école de la Santé, La SourceAcademic/Hospital2012017
Malaria Research and Training Center, Bamako, MaliAcademic/Hospital2012017
Moorgreen Hospital, SouthamptonAcademic/Hospital2012013
National Institute for Health Research, United KingdomGovernment2012014
United States Agency for International DevelopmentGovernment2022006
Centre for the AIDS Programme of Research in South AfricaGovernment1012016
Department of DefenseGovernment1012010
George Washington UniversityAcademic/Hospital1012018
Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO)Academic/Hospital1012020
Institut Paoli-CalmettesAcademic/Hospital1112013
International AIDS Vaccine InitiativeAcademic/Hospital1112018
Mahidol UniversityAcademic/Hospital1012017
Sanofi-AventisFor profit1012017
24 organizations
Page 1 / 2